The DDAH2 (dimethylarginine dimethylaminohydrolase 2) antibody is a research tool used to study the enzyme DDAH2. which plays a critical role in regulating nitric oxide (NO) synthesis. DDAH2 catalyzes the hydrolysis of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase (NOS). By breaking down ADMA, DDAH2 enhances NO production, a key signaling molecule involved in vasodilation, endothelial function, and cardiovascular homeostasis. Dysregulation of DDAH2 has been linked to cardiovascular diseases, including hypertension, atherosclerosis, and ischemia-reperfusion injury, as well as inflammatory and metabolic disorders.
The DDAH2 antibody enables detection and quantification of the enzyme in various experimental models, such as Western blotting, immunohistochemistry, and ELISA. It helps researchers investigate tissue-specific expression patterns, subcellular localization (e.g., mitochondrial association in some cell types), and dynamic changes in DDAH2 levels under physiological or pathological conditions. Studies using this antibody have contributed to understanding DDAH2's role in oxidative stress, angiogenesis, and cellular survival pathways. Species-specific and cross-reactive variants are available, supporting research in humans, rodents, and other model organisms. Its application is pivotal in exploring therapeutic strategies targeting the ADMA-DDAH2-NO axis for cardiovascular and metabolic diseases.